3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Anus Neoplasms
1
Interventions
pembrolizumab
24
Paclitaxel
11
Carboplatin
11
Trastuzumab
9
Nivolumab
7
Fulvestrant
6
palbociclib
4
olaparib
4
Taxes
4
Surveys and Questionnaires
4
Methods
4
Early Intervention, Educational
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
pertuzumab
3
lenvatinib
3
fludarabine
3
atezolizumab
3
abemaciclib
3
Tamoxifen
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Metformin
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interviews as Topic
3
Gemcitabine
3
Counseling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Technetium-99
×
Breast
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled